FPTW
CVS icon

Franklin, Parlapiano, Turner & Welch’s CVS Health CVS Stock Holding History

Franklin, Parlapiano, Turner & Welch’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-75,473
Closed -$7.03M – 49
2022
Q4 		$7.03M Sell
75,473
-1,929
-2% -$186K 2.31% 21
2022
Q3 		$7.38M Sell
77,402
-1,835
-2% -$182K 2.63% 6
2022
Q2 		$7.34M Sell
79,237
-3,102
-4% -$303K 2.48% 9
2022
Q1 		$8.33M Sell
82,339
-2,698
-3% -$283K 2.48% 8
2021
Q4 		$8.77M Sell
85,037
-2,757
-3% -$255K 2.52% 7
2021
Q3 		$7.45M Sell
87,794
-1,191
-1% -$99.8K 2.34% 8
2021
Q2 		$7.42M Sell
88,985
-354
-0.4% -$29K 2.29% 9
2021
Q1 		$6.72M Buy
89,339
+2,367
+3% +$172K 2.26% 15
2020
Q4 		$5.94M Buy
86,972
+2,352
+3% +$153K 2.15% 20
2020
Q3 		$4.94M Sell
84,620
-4
-0% -$249 2% 21
2020
Q2 		$5.5M Sell
84,624
-2,675
-3% -$168K 2.27% 14
2020
Q1 		$5.18M Buy
87,299
+46
+0.1% +$3.07K 2.38% 13
2019
Q4 		$6.48M Sell
87,253
-3,293
-4% -$231K 2.44% 9
2019
Q3 		$5.71M Buy
90,546
+3,970
+5% +$235K 2.22% 16
2019
Q2 		$4.72M Buy
86,576
+18,849
+28% +$1.02M 1.85% 24
2019
Q1 		$3.65M Buy
67,727
+6,054
+10% +$374K 1.44% 25
2018
Q4 		$4.04M Buy
61,673
+1,547
+3% +$115K 1.78% 24
2018
Q3 		$4.73M Buy
60,126
+2,216
+4% +$158K 1.89% 20
2018
Q2 		$3.73M Buy
57,910
+2,836
+5% +$187K 1.54% 24
2018
Q1 		$3.43M Buy
55,074
+1,828
+3% +$131K 1.46% 25
2017
Q4 		$3.86M Buy
53,246
+3,367
+7% +$245K 1.58% 25
2017
Q3 		$4.06M Buy
49,879
+4,173
+9% +$330K 1.74% 23
2017
Q2 		$3.68M Buy
45,706
+1,442
+3% +$114K 1.68% 23
2017
Q1 		$3.48M Buy
44,264
+2,189
+5% +$175K 1.61% 25
2016
Q4 		$3.32M Buy
42,075
+902
+2% +$73K 1.65% 24
2016
Q3 		$3.66M Buy
41,173
+3,011
+8% +$284K 1.86% 20
2016
Q2 		$3.65M Sell
38,162
-1,031
-3% -$103K 1.95% 18
2016
Q1 		$4.07M Buy
39,193
+38,946
+15,768% +$3.79M 2.24% 9
2015
Q4 		$24K Buy
+247
New +$24.2K 0.01% 86

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Franklin, Parlapiano, Turner & Welch's CVS Position: Q1 2023 in Review

Franklin, Parlapiano, Turner & Welch sold out of CVS Health (CVS) in Q1 2023, closing a stake of 75,473 shares — an estimated $7.03M sold.

Franklin, Parlapiano, Turner & Welch first reported a position in CVS in Q4 2015 and held it in 29 quarters. The position peaked at $8.77M in Q4 2021. 2,267 funds tracked by Wall St. Rank hold CVS as of Q1 2023.

  • Franklin, Parlapiano, Turner & Welch reported no remaining CVS Health position as of Q1 2023 after selling out during the quarter.
  • Franklin, Parlapiano, Turner & Welch sold 75,473 CVS Health shares in Q1 2023, an estimated $7.03M.
  • Franklin, Parlapiano, Turner & Welch first reported a position in CVS Health in Q4 2015 and held it in 29 quarters.
  • Franklin, Parlapiano, Turner & Welch's CVS Health position peaked at $8.77M in Q4 2021.
  • 2,267 funds tracked by Wall St. Rank held CVS Health as of Q1 2023.

Based on Franklin, Parlapiano, Turner & Welch's 13F filing for Q1 2023, filed 2 May 2023.